Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression
Vincent Van den Eynde, Wegdan R. Abdelmoemin, Magid M. Abraham, et al.
CNS Spectrums (2022) Vol. 28, Iss. 4, pp. 427-440
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Depression and Anxiety Disorders
Oğuz Karamustafalıoğlu, Hüseyin Yumrukçal
(2025), pp. 335-476
Closed Access | Times Cited: 7
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024
Antoine Yrondi, Hervé Javelot, Bénédicte Nobile, et al.
L Encéphale (2024)
Closed Access | Times Cited: 6
Tyramine, a biogenic agent in cheese: amount and factors affecting its formation, a systematic review
Parisa Sadighara, Saeed Aghebat- Bekheir, Hamed Shafaroodi, et al.
Food Production Processing and Nutrition (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 6
Machine learning accelerates pharmacophore-based virtual screening of MAO inhibitors
Marcin Cieślak, Tomasz Danel, Olga Krzysztyńska‐Kuleta, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Monoamine oxidase and neurodegeneration: mechanisms, inhibitors and natural compounds for therapeutic intervention.
Chayan Banerjee, Debasmita Tripathy, Deepak Kumar, et al.
Neurochemistry International (2024) Vol. 179, pp. 105831-105831
Closed Access | Times Cited: 5
Pyrazoline Derivatives as Promising MAO-A Targeting Antidepressants: An Update
Diksha Choudhary, Rajwinder Kaur, Thakur Gurjeet Singh, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 5, pp. 401-415
Closed Access | Times Cited: 4
Trajectory and Magnitude of Response in Adults with Anxiety Disorders: A Bayesian Hierarchical Modeling Meta-Analysis of Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors and Benzodiazepines
Eric Mendez, Jeffrey A. Mills, Vikram Suresh, et al.
CNS Spectrums (2024) Vol. 29, Iss. 3, pp. 187-196
Closed Access | Times Cited: 3
Convulsive therapy for psychiatric disorders
Tyler S. Kaster, Daniel M. Blumberger
Elsevier eBooks (2024), pp. 241-285
Closed Access | Times Cited: 2
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
Val Bellman
Cancers (2024) Vol. 16, Iss. 9, pp. 1702-1702
Open Access | Times Cited: 2
Monoamine Oxidase Inhibitors and Clinically Relevant Drug Interactions: A Guide for Preventing Serotonin Toxicity and Hypertensive Reactions
P. Ken Gillman, Vincent Van den Eynde, Lila Godet, et al.
Psychiatric Annals (2023) Vol. 53, Iss. 8, pp. 353-358
Closed Access | Times Cited: 6
Expert Opinion on Anesthetic Considerations For Patients Receiving a Classic Monoamine Oxidase Inhibitor
Harvey K. Rosenbaum, Vincent Van den Eynde, P. Ken Gillman
Anesthesia & Analgesia (2024) Vol. 139, Iss. 4, pp. 863-866
Closed Access | Times Cited: 2
Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine
Gavin R. Hoffman, Madeline G. Olson, Allen M. Schoffstall, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 23, pp. 4064-4075
Closed Access | Times Cited: 6
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations
Flavia Rossano, Claudio Caiazza, Andrea Sobrino, et al.
European Neuropsychopharmacology (2023) Vol. 72, pp. 60-78
Closed Access | Times Cited: 5
Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis
Anna Giménez‐Palomo, Anjli K. Chamdal, Natalie Gottlieb, et al.
Acta Psychiatrica Scandinavica (2024) Vol. 150, Iss. 6, pp. 500-515
Closed Access | Times Cited: 1
Ginsenoside Rg1: A Neuroprotective Natural Dammarane‐Type Triterpenoid Saponin With Anti‐Depressive Properties
Dong Han, Zheng Zhao, Tianyang Mao, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 12
Closed Access | Times Cited: 1
Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression
Ludovic C. Dormegny-Jeanjean, Olivier Mainberger, Clément de Crespin de Billy, et al.
L Encéphale (2023) Vol. 50, Iss. 2, pp. 137-142
Closed Access | Times Cited: 2
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?
Přemysl Vlček, Petr Bob, Karel Valeš
Journal of Psychopharmacology (2023) Vol. 37, Iss. 11, pp. 1157-1160
Closed Access | Times Cited: 2
Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study
Thomas T. Kim, Jay D. Amsterdam
Acta Psychiatrica Scandinavica (2022) Vol. 147, Iss. 2, pp. 198-204
Closed Access | Times Cited: 4
Mood Disorders
Robert D. Beech
Elsevier eBooks (2024)
Closed Access
1-(Phenylselanyl)-2-(p-tolyl)indolizine: A selenoindolizine with potential antidepressant-like activity in mice mediated by the modulation of dopaminergic and noradrenergic systems
Marcia Juciele da Rocha, Marcelo Heinemann Presa, Gustavo D’Avila Nunes, et al.
Brain Research (2024) Vol. 1834, pp. 148904-148904
Closed Access
Synthesis, in silico, and in vitro evaluation of 7-chloro-quinolines designed as myeloperoxidase inhibitors
Gabriel Rodrigues Coutinho Pereira, Letícia de Souza Fraga, Rômulo Pereira de Jesus, et al.
Journal of Molecular Structure (2024) Vol. 1312, pp. 138528-138528
Closed Access
Construction of an antidepressant priority list based on functional, environmental, and health risks using an interpretable mixup-transformer deep learning model
Peixuan Sun, Huaishi Liu, Yuanyuan Zhao, et al.
Journal of Hazardous Materials (2024) Vol. 474, pp. 134651-134651
Closed Access
Management of Depression
S. Shalom Feinberg
JAMA (2024) Vol. 332, Iss. 19, pp. 1673-1673
Closed Access
Exploring the contribution of the dopaminergic and noradrenergic systems in the antidepressant-like action of 1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone in mice
Marcelo Heinemann Presa, Marcia Juciele da Rocha, Kauane Nayara Bahr Ledebuhr, et al.
Behavioural Brain Research (2024) Vol. 480, pp. 115390-115390
Closed Access
The highs and lows of monoamine oxidase as molecular target in cancer: an updated review
Iasmina M. Hâncu, Silvia Giuchici, Adina V. Furdui-Lința, et al.
Molecular and Cellular Biochemistry (2024)
Open Access
Page 1 - Next Page

Scroll to top